A mitochondrial basis for Huntington's disease: Therapeutic prospects

Molecular and Cellular Biochemistry

Volumn 389, Issue 1-2, 2014, Pages 277-291

  Chakraborty, J ^a   Rajamma, U ^b   Mohanakumar, K P ^a  

^a INDIAN INSTITUTE OF CHEMICAL BIOLOGY   (India)

^b Manovikas Biomedical Research and Diagnostic Centre   (India)

Author keywords

Dynamin related protein 1; Mitochondria as a therapeutic target; Mitochondrial biogenesis; Mitochondrial ETC complex activity; Mitofusin 1 2; Mutant Huntingtin

Indexed keywords

ACETYLSALICYLIC ACID; AMANTADINE; CALCIUM ION; CLONAZEPAM; CLOZAPINE; CREATINE; DIAZEPAM; DICHLOROACETIC ACID; DIMEBON; DOPA; DOPAMINE; ETIRACETAM; FAS LIGAND; GABAPENTIN; GLUTAMIC ACID; HALOPERIDOL; HUNTINGTIN; LACTAM; LAMOTRIGINE; LITHIUM; MELATONIN; MEMANTINE; MINOCYCLINE; RAPAMYCIN; TETRABENAZINE; THIOCTIC ACID; TREHALOSE; TUMOR NECROSIS FACTOR ALPHA; UBIDECARENONE;

APOPTOSIS; BRAIN MITOCHONDRION; CALCIUM TRANSPORT; CORPUS STRIATUM; DISEASE MODEL; EXPERIMENTAL MODEL; HUMAN; HUNTINGTON CHOREA; INTRACELLULAR TRANSPORT; MOLECULAR MODEL; NERVE CELL NECROSIS; NERVE DEGENERATION; NEUROPATHOLOGY; NONHUMAN; ORGANELLE SHAPE; PROTEIN AGGREGATION; REGULATORY MECHANISM; REVIEW;

ANIMALS; BRAIN; CELL DEATH; GLUTAMIC ACID; HUMANS; HUNTINGTON DISEASE; MITOCHONDRIA; NERVE TISSUE PROTEINS;

EID: 84896549657     PISSN: 03008177     EISSN: 15734919     Source Type: Journal    
DOI: 10.1007/s11010-013-1951-9     Document Type: Review

References (193)

1. The Huntington's disease collaborative research group (1993) A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72:971-983
2. Rubinsztein DC, Leggo J, Coles R et al (1996) Phenotypic characterization of individuals with 30-40 CAG repeats in the Huntington disease (HD) gene reveals HD cases with 36 repeats and apparently normal elderly individuals with 36-39 repeats. Am J Hum Genet 59:16-22 (Pubitemid 26189723)
3. Nørremølle A, Riess O, Epplen JT, Fenger K, Hasholt L, Sørensen SA (1993) Trinucleotide repeat elongation in the Huntingtin gene in Huntington disease patients from 71 Danish families. Hum Mol Genet 2:1475-1476
4. Zühlke C, Riess O, Bockel B, Lange H, Thies U (1993) Mitotic stability and meiotic variability of the (CAG)n repeat in the Huntington disease gene. Hum Mol Genet 2:2063-2067 (Pubitemid 24003399)
5. Sharp AH, Love SJ, Schilling G et al (1995) Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 14:1065-1074
6. Nasir J, Floresco SB, O'Kusky JR et al (1995) Targeted disruption of the Huntington's disease gene results in embryonic lethality and behavioral and morphological changes in heterozygotes. Cell 81:811-823
7. Hodgson JG, Agopyan N, Gutekunst CA et al (1999) A YAC mouse model for Huntington's disease with full-length mutant Huntingtin, cytoplasmic toxicity, and selective striatal neurodegeneration. Neuron 23:181-192 (Pubitemid 29262475)
8. Trushina E, Dyer RB, Badger JD et al (2004) Mutant Huntingtin impairs axonal trafficking in mammalian neurons in vivo and in vitro. Mol Cell Biol 24:8195-8209 (Pubitemid 39167467)
9. Sugars KL, Rubinsztein DC (2003) Transcriptional abnormalities in Huntington disease. Trends Genet 19:233-238 (Pubitemid 36511427)
10. Borgonovo JE, Troncoso M, Lucas JJ, Sosa MA (2013) Mutant Huntingtin affects endocytosis in striatal cells by altering the binding of AP-2 to membranes. Exp Neurol 241:75-83
11. Trushina E, Singh RD, Dyer RB, Cao S, Shah VH, Parton RG, Pagano RE, McMurray CT (2006) Mutant Huntingtin inhibits clathrin-independent endocytosis and causes accumulation of cholesterol in vitro and in vivo. Hum Mol Genet 15:3578-3591 (Pubitemid 44884124)
12. Atwal RS, Truant R (2008) A stress sensitive ER membrane-association domain in Huntingtin protein defines a potential role for Huntingtin in the regulation of autophagy. Autophagy 4:91-93
13. Rockabrand E, Slepko N, Pantalone A et al (2007) The first 17 amino acids of Huntingtin modulate its sub-cellular localization, aggregation and effects on calcium homeostasis. Hum Mol Genet 16:61-77 (Pubitemid 46156597)
14. Panov AV, Gutekunst CA, Leavitt BR, Hayden MR, Burke JR, Strittmatter WJ, Greenamyre JT (2002) Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines. Nat Neurosci 5:731-736 (Pubitemid 34827590)
15. Napolitano M, Centonze D, Gubellini P, Rossi S, Spiezia S, Bernardi G, Gulino A, Calabresi P (2004) Inhibition of mitochondrial complex II alters striatal expression of genes involved in glutamatergic and dopaminergic signaling: possible implications for Huntington's disease. Neurobiol Dis 15:407-414 (Pubitemid 38296771)
16. Pandey M, Borah A, Varghese M, Barman PK, Mohanakumar KP, Usha R (2009) Striatal dopamine level contributes to hydroxyl radical generation and subsequent neurodegeneration in the striatum in 3-nitropropionic acid-induced Huntington's disease in rats. Neurochem Int 55:431-437
17. Hansson O, Guatteo E, Mercuri NB, Bernardi G, Li XJ, Castilho RF, Brundin P (2001) Resistance to NMDA toxicity correlates with appearance of nuclear inclusions, behavioural deficits and changes in calcium homeostasis in mice transgenic for exon 1 of the Huntington gene. Eur J Neurosci 14:1492-1504 (Pubitemid 35463716)
18. Hansson O, Petersén A, Leist M, Nicotera P, Castilho RF, Brundin P (1999) Transgenic mice expressing a Huntington's disease mutation are resistant to quinolinic acid-induced striatal excitotoxicity. Proc Natl Acad Sci USA 96:8727-8732 (Pubitemid 29354859)
19. 2+ and respiratory chain complex II inhibition. J Neurochem 90:1025-1035
20. La Fontaine MA, Geddes JW, Banks A, Butterfield DA (2000) 3-Nitropropionic acid-induced in vivo protein oxidation in striatal and cortical synaptosomes: insights into Huntington's disease. Brain Res 858:356-362 (Pubitemid 30119997)
21. Tabrizi SJ, Cleeter MWJ, Xuereb J, Taanman JW, Cooper JM, Schapira AHV (1999) Biochemical abnormalities and excitotoxicity in Huntington's disease brain. Ann Neurol 45:25-32 (Pubitemid 29036428)
22. Chen CM, Wu YR, Cheng ML, Liu JL, Lee YM, Lee PW, Soong BW, Chiu DTY (2007) Increased oxidative damage and mitochondrial abnormalities in the peripheral blood of Huntington's disease patients. Biochem Biophys Res Com 359:335-340
23. del Hoyo P, Redondo AG, de Bustos F et al (2006) Oxidative stress in skin fibroblasts cultures of patients with Huntington's disease. Neurochem Res 31:1103-1109
24. Cyr M, Beaulieu JM, Laakso A et al (2003) Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc Natl Acad Sci USA 100:11035-11040 (Pubitemid 37140148)
25. Benchoua A, Trioulier Y, Diguet E et al (2008) Dopamine determines the vulnerability of striatal neurons to the N-terminal fragment of mutant Huntingtin through the regulation of mitochondrial complex II. Hum Mol Genet 17:1446-1456 (Pubitemid 351627341)
26. Beal MF, Brouillet E, Jenkins BG (1993) Neurochemical and histologic characterization of striatal excitotoxic lesions produced by the mitochondrial toxin 3-nitropropionic acid. J Neurosci 13:4181-4192 (Pubitemid 23299942)
27. Pandey M, Varghese M, Sindhu KM, Sreetama S, Navneet AK, Mohanakumar KP, Usha R (2008) Mitochondrial NAD+-linked State 3 respiration and complex-I activity are compromised in the cerebral cortex of 3-nitropropionic acid-induced rat model of Huntington's disease. J Neurochem 104:420-434 (Pubitemid 350293876)
28. Nekooki-Machida Y, Kurosawa M, Nukina N, Ito K, Oda T, Tanaka M (2009) Distinct conformations of in vitro and in vivo amyloids of Huntingtin-exon1 show different cytotoxicity. Proc Natl Acad Sci USA 106:9679-9684
29. Cooper JK, Schilling G, Peters MF et al (1998) Truncated N-terminal fragments of Huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum Mol Genet 7:783-790 (Pubitemid 28221240)
30. Yang W, Dunlap JR, Andrews RB, Wetzel R (2002) Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. Hum Mol Genet 11:2905-2917
31. Arrasate M, Mitra S, Schweitzer ES, Segal MR, Finkbeiner S (2004) Inclusion body formation reduces levels of mutant Huntingtin and the risk of neuronal death. Nature 431:805-810 (Pubitemid 39434070)
32. DiFiglia M, Sapp E, Chase KO, Davies SW, Bates GP, Vonsattel JP, Aronin N (1997) Aggregation of Huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277:1990-1993 (Pubitemid 27449140)
33. Song W, Chen J, Petrilli A (2011) Mutant Huntingtin binds the mitochondrial fission GTPase dynamin-related protein-1 and increases its enzymatic activity. Nat Med 17:377-382
34. Shirendeb U, Reddy AP, Manczak M, Calkins MJ, Mao P, Tagle DA, Reddy PH (2011) Abnormal mitochondrial dynamics, mitochondrial loss and mutant Huntingtin oligomers in Huntington's disease: implications for selective neuronal damage. Hum Mol Genet 20:1438-1455
35. Browne SE, Bowling AC, MacGarvey U, Baik MJ, Berger SC, Muqit MM, Bird ED, Beal MF (1997) Oxidative damage and metabolic dysfunction in Huntington's disease: selective vulnerability of the basal ganglia. Ann Neurol 41:646-653 (Pubitemid 27212659)
36. Shirendeb UP, Calkins MJ, Manczak M, Anekonda V, Dufour B, McBride JL, Mao P, Reddy PH (2012) Mutant Huntingtin's interaction with mitochondrial protein Drp1 impairs mitochondrial biogenesis and causes defective axonal transport and synaptic degeneration in Huntington's disease. Hum Mol Genet 21:406-420
37. Gu M, Gash MT, Mann VM, Javoy-Agid F, Cooper JM, Schapira AH (1996) Mitochondrial defect in Huntington's disease caudate nucleus. Ann Neurol 39:385-389 (Pubitemid 26100764)
38. Arenas J, Campos Y, Ribacoba R, Martín MA, Rubio JC, Ablanedo P, Cabello A (1998) Complex I defect in muscle from patients with Huntington's disease. Ann Neurol 43:397-400 (Pubitemid 28113606)
39. Benchoua A, Trioulier Y, Zala D et al (2006) Involvement of mitochondrial complex II defects in neuronal death produced by N-terminus fragment of mutated Huntingtin. Mol Biol Cell 17:1652-1663 (Pubitemid 44011583)
40. Brouillet E, Hantraye P, Ferrante RJ, Dolan R, Leroy-Willig A, Kowall NW, Beal MF (1995) Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc Natl Acad Sci USA 92:7105-7109
41. Brouillet E, Jacquard C, Bizat N, Blum D (2005) 3-Nitropropionic acid: a mitochondrial toxin to uncover physiopathological mechanisms underlying striatal degeneration in Huntington's disease. J Neurochem 95:1521-1540 (Pubitemid 41804051)
42. Brouillet E, Jenkins BG, Hyman BT et al (1993) Age-dependent vulnerability of the striatum to the mitochondrial toxin 3-nitropropionic acid. J Neurochem 60:356-359 (Pubitemid 23006739)
43. Ludolph AC, He F, Spencer PS, Hammerstad J, Sabri M (1991) 3-Nitropropionic acid-exogenous animal neurotoxin and possible human striatal toxin. Can J Neurol Sci 18:492-498
44. Palfi S, Ferrante RJ, Brouillet E, Beal MF, Dolan R, Guyot MC, Peschanski M, Hantraye P (1996) Chronic 3-nitropropionic acid treatment in baboons replicates the cognitive and motor deficits of Huntington's disease. J Neurosci 16:3019-3025 (Pubitemid 26121844)
45. Jana NR, Zemskov EA, Wang Gh, Nukina N (2001) Altered proteasomal function due to the expression of polyglutamine-expanded truncated N-terminal Huntingtin induces apoptosis by caspase activation through mitochondrial cytochrome c release. Hum Mol Genet 10:1049-1059 (Pubitemid 32447782)
46. Fukui H, Moraes CT (2007) Extended polyglutamine repeats trigger a feedback loop involving the mitochondrial complex III, the proteasome and Huntingtin aggregates. Hum Mol Genet 16:783-797 (Pubitemid 47061625)
47. Polidori MC, Mecocci P, Browne SE, Senin U, Beal MF (1999) Oxidative damage to mitochondrial DNA in Huntington's disease parietal cortex. Neurosci Lett 272:53-56
48. Braak H, Braak E (1992) Allocortical involvement in Huntington's disease. Neuropathol Appl Neurobiol 18:539-547 (Pubitemid 23010156)
49. Lehman JJ, Barger PM, Kovacs A, Saffitz JE, Medeiros DM, Kelly DP (2000) Peroxisome proliferator-activated receptor gamma coactivator-1 promotes cardiac mitochondrial biogenesis. J Clin Invest 106:847-856
50. Wu Z, Puigserver P, Andersson U et al (1999) Mechanisms controlling mitochondrial biogenesis and respiration through the thermogenic coactivator PGC-1. Cell 98:115-124 (Pubitemid 29331201)
51. Cui L, Jeong H, Borovecki F, Parkhurst CN, Tanese N, Krainc D (2006) Transcriptional repression of PGC-1alpha by mutant Huntingtin leads to mitochondrial dysfunction and neurodegeneration. Cell 127:59-69 (Pubitemid 44466642)
52. Chaturvedi RK, Adhihetty P, Shukla S et al (2009) Impaired PGC-1a function in muscle in Huntington's disease. Hum Mol Genet 18:3048-3065
53. Weydt P, Pineda VV, Torrence AE et al (2006) Thermoregulatory and metabolic defects in Huntington's disease transgenic mice implicate PGC-1alpha in Huntington's disease neurodegeneration. Cell Metab 4:349-362 (Pubitemid 44645069)
54. Fernandes HB, Baimbridge KG, Church J, Hayden MR, Raymond LA (2007) Mitochondrial sensitivity and altered calcium handling underlie enhanced NMDA-induced apoptosis in YAC128 model of Huntington's disease. J Neurosci 27:13614-13623 (Pubitemid 350278271)
55. 2+-induced permeability transition in human lymphoblastoid cell mitochondria from normal and Huntington's disease individuals. Mol Cell Biochem 269:143-152
56. Rosenstock TR, Carvalho AC, Jurkiewicz A, Frussa-Filho R, Smaili SS (2004) Mitochondrial calcium, oxidative stress and apoptosis in a neurodegenerative disease model induced by 3-nitropropionic acid. J Neurochem 88:1220-1228 (Pubitemid 38280690)
57. Smirnova E, Griparic L, Shurland DL, van der Bliek AM (2001) Dynamin-related protein Drp1 is required for mitochondrial division in mammalian cells. Mol Biol Cell 12:2245-2256 (Pubitemid 33051954)
58. Cereghetti GM, Stangherlin A, Martins de Brito O (2008) Dephosphorylation by calcineurin regulates translocation of Drp1 to mitochondria. Proc Natl Acad Sci USA 105:15803-15808
59. Cribbs JT, Strack S (2007) Reversible phosphorylation of Drp1 by cyclic AMP-dependent protein kinase and calcineurin regulates mitochondrial fission and cell death. EMBO Rep 8:939-944 (Pubitemid 47500477)
60. Harder Z, Zunino R, McBride H (2004) Sumo1 conjugates mitochondrial substrates and participates in mitochondrial fission. Curr Biol 14:340-345 (Pubitemid 38300214)
61. Karbowski M, Neutzner A, Youle RJ (2007) The mitochondrial E3 ubiquitin ligase MARCH5 is required for Drp1 dependent mitochondrial division. J Cell Biol 178:71-84 (Pubitemid 47026403)
62. Park YY, Lee S, Karbowski M, Neutzner A, Youle RJ, Cho H (2010) Loss of MARCH5 mitochondrial E3 ubiquitin ligase induces cellular senescence through dynamin-related protein 1 and mitofusin 1. J Cell Sci 123:619-626
63. Taguchi N, Ishihara N, Jofuku A, Oka T, Mihara K (2007) Mitotic phosphorylation of dynamin-related GTPase Drp1 participates in mitochondrial fission. J Biol Chem 282:11521-11529 (Pubitemid 47100787)
64. Zunino R, Schauss A, Rippstein P, Andrade-Navarro M, McBride HM (2007) The SUMO protease SENP5 is required to maintain mitochondrial morphology and function. J Cell Sci 120:1178-1188 (Pubitemid 46711836)
65. Nakamura T, Cieplak P, Cho DH, Godzik A, Lipton SA (2010) S-nitrosylation of Drp1 links excessive mitochondrial fission to neuronal injury in neurodegeneration. Mitochondrion 10:573-578
66. Wang H, Lim PJ, Karbowski M, Monteiro MJ (2009) Effects of overexpression of Huntingtin proteins on mitochondrial integrity. Hum Mol Genet 18:737-752
67. Costa V, Giacomello M, Hudec R (2010) Mitochondrial fission and cristae disruption increase the response of cell models of Huntington's disease to apoptotic stimuli. EMBO Mol Med 2:490-503
68. Liot G, Bossy B, Lubitz S, Kushnareva Y, Sejbuk N, Bossy-Wetzel E (2009) Complex II inhibition by 3-NP causes mitochondrial fragmentation and neuronal cell death via an NMDA-and ROS-dependent pathway. Cell Death Differ 16:899-909
69. Haun F, Nakamura T, Shiu AD, Cho DH, Tsunemi T, Holland EA, La Spada AR, Lipton SA (2013) S-Nitrosylation of dynamin-related protein 1 mediates mutant Huntingtin-induced mitochondrial fragmentation and neuronal injury in Huntington's disease. Antioxid Redox Signal 19:1173-1184
70. Baqri RM, Turner BA, Rheuben MB, Hammond BD, Kaguni LS, Miller KE (2009) Disruption of mitochondrial DNA replication in Drosophila increases mitochondrial fast axonal transport in vivo. PLoS One 4:e7874
71. Miller KE, Sheetz MP (2004) Axonal mitochondrial transport and potential are correlated. J Cell Sci 117:2791-2804 (Pubitemid 38997261)
72. Hollenbeck PJ, Saxton WM (2005) The axonal transport of mitochondria. J Cell Sci 118:5411-5419 (Pubitemid 43079283)
73. Saxton WM, Hollenbeck PJ (2012) The axonal transport of mitochondria. J Cell Sci 125:2095-2104
74. Guo X, Macleod GT, Wellington A (2005) The GTPase dMiro is required for axonal transport of mitochondria to Drosophila synapses. Neuron 47:379-393 (Pubitemid 41073879)
75. Reis K, Fransson A, Aspenström P (2009) The Miro GTPases: at the heart of the mitochondrial transport machinery. FEBS Lett 583:1391-1398
76. MacAskill AF, Brickley K, Stephenson FA, Kittler JT (2009) GTPase dependent recruitment of Grif-1 by Miro1 regulates mitochondrial trafficking in hippocampal neurons. Mol Cell Neurosci 40:301-312
77. Su Q, Cai Q, Gerwin C, Smith CL, Sheng ZH (2004) Syntabulin is a microtubule-associated protein implicated in syntaxin transport in neurons. Nat Cell Biol 6:941-953 (Pubitemid 39359847)
78. Ma H, Cai Q, Lu W, Sheng ZH, Mochida S (2009) KIF5B motor adaptor syntabulin maintains synaptic transmission in sympathetic neurons. J Neurosci 29:13019-13029
79. MacAskill AF, Kittler JT (2010) Control of mitochondrial transport and localization in neurons. Trends Cell Biol 20:102-112
80. Schwarzer C, Barnikol-Watanabe S, Thinnes FP, Hilschmann N (2002) Voltage-dependent anion-selective channel (VDAC) interacts with the dynein light chain Tctex1 and the heat-shock protein PBP74. Int J Biochem Cell Biol 34:1059-1070 (Pubitemid 34493767)
81. Ohno N, Kidd GJ, Mahad D, Kiryu-Seo S, Avishai A, Komuro H, Trapp BD (2011) Myelination and axonal electrical activity modulate the distribution and motility of mitochondria at CNS nodes of Ranvier. J Neurosci 31:7249-7258
82. Rintoul GL, Bennett VJ, Papaconstandinou NA, Reynolds IJ (2006) Nitric oxide inhibits mitochondrial movement in forebrain neurons associated with disruption of mitochondrial membrane potential. J Neurochem 97:800-806
83. Rintoul GL, Filiano AJ, Brocard JB, Kress GJ, Reynolds IJ (2003) Glutamate decreases mitochondrial size and movement in primary forebrain neurons. J Neurosci 23:7881-7888 (Pubitemid 37052356)
84. Müller M, Mironov SL, Ivannikov MV, Schmidt J, Richter DW (2005) Mitochondrial organization and motility probed by two-photon microscopy in cultured mouse brainstem neurons. Exp Cell Res 303:114-127 (Pubitemid 39575148)
85. Zanelli SA, Trimmer PA, Solenski NJ (2006) Nitric oxide impairs mitochondrial movement in cortical neurons during hypoxia. J Neurochem 97:724-736
86. Zhang CL, Ho PL, Kintner DB, Sun D, Chiu SY (2010) Activity-dependent regulation of mitochondrial motility by calcium and Na/K-ATPase at nodes of Ranvier of myelinated nerves. J Neurosci 30:3555-3566
87. Misko A, Jiang S, Wegorzewska I, Milbrandt J, Baloh RH (2010) Mitofusin 2 is necessary for transport of axonal mitochondria and interacts with the Miro/Milton complex. J Neurosci 30:4232-4240
88. Chang DT, Rintoul GL, Pandipati S, Reynolds IJ (2006) Mutant Huntingtin aggregates impair mitochondrial movement and trafficking in cortical neurons. Neurobiol Dis 22:388-400
89. Orr AL, Li S, Wang CE, Li H (2008) N-terminal mutant Huntingtin associates with mitochondria and impairs mitochondrial trafficking. J Neurosci 28:2783-2792 (Pubitemid 351398886)
90. Gauthier LR, Charrin BC, Borrell-Pagès M (2004) Huntingtin controls neurotrophic support and survival of neurons by enhancing BDNF vesicular transport along microtubules. Cell 118:127-138 (Pubitemid 38902819)
91. McGuire JR, Rong J, Li SH, Li XJ (2006) Interaction of Huntingtin-associated protein-1 with kinesin light chain: implications in intracellular trafficking in neurons. J Biol Chem 281:3552-3559 (Pubitemid 43845972)
92. Costa V, Scorrano L (2012) Shaping the role of mitochondria in the pathogenesis of Huntington's disease. EMBO J 31:1853-1864
93. Bae BI, Xu H, Igarashi S et al (2005) p53 mediates cellular dysfunction and behavioral abnormalities in Huntington's disease. Neuron 47:29-41 (Pubitemid 40922848)
94. Zeron MM, Chen N, Moshaver A et al (2001) Mutant Huntingtin enhances excitotoxic cell death. Mol Cell Neurosci 17:41-53 (Pubitemid 32113537)
95. Holmberg CI, Staniszewski KE, Mensah KN, Matouschek A, Morimoto RI (2004) Inefficient degradation of truncated polyglutamine proteins by the proteasome. EMBO J 23:4307-4318 (Pubitemid 39546168)
96. Saudou F, Finkbeiner S, Devys D, Greenberg ME (1998) Huntingtin acts in the nucleus to induce apoptosis but death does not correlate with the formation of intranuclear inclusions. Cell 95:55-66
97. Song W, Smith MR, Syed A (2013) Morphometric analysis of Huntington's disease neurodegeneration in Drosophila. Methods Mol Biol 1017:41-57
98. Diekmann H, Anichtchik O, Fleming A et al (2009) Decreased BDNF levels are a major contributor to the embryonic phenotype of Huntingtin knockdown zebrafish. J Neurosci 29:1343-1349
99. Mason RP, Casu M, Butler N (2013) Gutathione peroxidase activity is neuroprotective in models of Huntington's disease. Nat Genet 45:1249-1254
100. Mangiarini L, Sathasivam K, Mahal A, Mott R, Seller M, Bates GP (1997) Instability of highly expanded CAG repeats in mice transgenic for the Huntington's disease mutation. Nat Genet 15:197-200 (Pubitemid 27061643)
101. Acevedo-Torres K, Berríos L, Rosario N et al (2009) Mitochondrial DNA damage is a hallmark of chemically induced and the R6/2 transgenic model of Huntington's disease. DNA Repair (Amst) 8:126-136
102. Bogdanov MB, Andreassen OA, Dedeoglu A, Ferrante RJ, Beal MF (2001) Increased oxidative damage to DNA in a transgenic mouse model of Huntington's disease. J Neurochem 79:1246-1249 (Pubitemid 34019802)
103. Kiechle T, Dedeoglu A, Kubilus J (2002) Cytochrome c and caspase-9 expression in Huntington's disease. Neuromolecular Med 1:183-195 (Pubitemid 37012515)
104. Bett JS, Goellner GM, Woodman B, Pratt G, Rechsteiner M, Bates GP (2006) Proteasome impairment does not contribute to pathogenesis in R6/2 Huntington's disease mice: exclusion of proteasome activator REG gamma as a therapeutic target. Hum Mol Genet 15:33-44 (Pubitemid 43020102)
105. Seo H, Kim W, Isacson O (2008) Compensatory changes in the ubiquitin-proteasome system, brain-derived neurotrophic factor and mitochondrial complex II/III in YAC72 and R6/2 transgenic mice partially model Huntington's disease patients. Hum Mol Genet 17:3144-3153
106. Schilling G, Becher MW, Sharp AH (1999) Intranuclear inclusions and neuritic aggregates in transgenic mice expressing a mutant N-terminal fragment of Huntingtin. Hum Mol Genet 8:397-407 (Pubitemid 29097327)
107. McGeer EG, McGeer PL (1976) Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acids. Nature 263:517-519
108. Coyle JT, Schwarcz R (1976) Lesion of striatal neurones with kainic acid provides a model for Huntington's chorea. Nature 263:244-246
109. Schwarcz R, Guidetti P, Sathyasaikumar KV, Muchowski PJ (2010) Of mice, rats and men: revisiting the quinolinic acid hypothesis of Huntington's disease. Prog Neurobiol 90:230-245
110. Beal MF, Kowall NW, Ellison DW, Mazurek MF, Swartz KJ, Martin JB (1986) Replication of the neurochemical characteristics of Huntington's disease by quinolinic acid. Nature 321:168-171 (Pubitemid 16022019)
111. Beal MF, Kowall NW, Swartz KJ, Ferrante RJ, Martin JB (1988) Systemic approaches to modifying quinolinic acid striatal lesions in rats. J Neurosci 8:3901-3908
112. Ferrante RJ, Kowall NW, Cipolloni PB, Storey E, Beal MF (1993) Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemicalcharacterization. Exp Neurol 119:46-71 (Pubitemid 23074242)
113. Solesio ME, Saez-Atienzar S, Jordan J, Galindo MF (2013) 3-Nitropropionic acid induces autophagy by forming mitochondrial permeability transition pores rather than activating the mitochondrial fission pathway. Br J Pharmacol 168:63-75
114. Bachurin SO, Shevtsova EP, Kireeva EG, Oxenkrug GF, Sablin SO (2003) Mitochondria as a target for neurotoxins and neuroprotective agents. Ann N Y Acad Sci 993:334-349
115. Doody RS, Gavrilova SI, Sano M, Thomas RG, Aisen PS, Bachurin SO, Seely L, Hung D (2008) Effect of dimebon on cognition, activities of daily living, behaviour, and global function in patients with mild-to-moderate Alzheimer's disease: a randomised, double-blind, placebo-controlled study. Lancet 372:207-215 (Pubitemid 351978110)
116. Wu J, Li Q, Bezprozvanny I (2008) Evaluation of Dimebon in cellular model of Huntington's disease. Mol Neurodegener 3:15
117. Bezprozvanny I (2010) The rise and fall of Dimebon. Drug News Perspect 23:518-523
118. 2: protection by melatonin and related molecules. J Pineal Res 29:54-61
119. Reiter RJ, Tan DX, Manchester LC, Qi W (2001) Biochemical reactivity of melatonin with reactive oxygen and nitrogen species: a review of the evidence. Cell Biochem Biophys 34:237-256 (Pubitemid 33615836)
120. Andrabi SA, Sayeed I, Siemen D, Wolf G, Horn TF (2004) Direct inhibition of the mitochondrial permeability transition pore: a possible mechanism responsible for anti-apoptotic effects of melatonin. FASEB J 18:869-871
121. Menendez-pelaez A, Reiter RJ (1993) Distribution of melatonin in mammalian tissues: the relative importance of nuclear versus cytosolic localization. J Pineal Res 15:59-69
122. Chetsawang B, Putthaprasart C, Phansuwan-Pujito P, Govitrapong P (2006) Melatonin protects against hydrogen peroxide-induced cell death signaling in SH-SY5Y cultured cells: involvement of nuclear factor kappa B, Bax and Bcl-2. J Pineal Res 41:116-123 (Pubitemid 44141745)
123. Wisessmith W, Phansuwan-Pujito P, Govitrapong P, Chetsawang B (2009) Melatonin reduces induction of Bax, caspase and cell death in methamphetamine-treated human neuroblastoma SH-SY5Y cultured cells. J Pineal Res 46:433-440
124. Alders J, Smits M, Kremer B, Naarding P (2009) The role of melatonin in sleep disturbances in end-stage Huntington's disease. J Neuropsychiatry Clin Neurosci 21:226-227
125. Aziz NA, Pijl H, Frölich M et al (2009) Delayed onset of the diurnal melatonin rise in patients with Huntington's disease. J Neurol 256:1961-1965
126. Morton AJ, Wood NI, Hastings MH (2005) Disintegration of the sleep-wake cycle and circadian timing in Huntington's disease. J Neurosci 25:157-163 (Pubitemid 40110776)
127. Nam E, Lee SM, Koh SE, Joo WS, Maeng S, Im HI, Kim YS (2005) Melatonin protects against neuronal damage induced by 3-nitropropionic acid in rat striatum. Brain Res 1046:90-96 (Pubitemid 40775877)
128. Túnez I, Montilla P, Del Carmen Muñoz M, Feijóo M, Salcedo M (2004) Protective effect of melatonin on 3-nitropropionic acid-induced oxidative stress in synaptosomes in an animal model of Huntington's disease. J Pineal Res 37:252-256 (Pubitemid 39457046)
129. Tasset I, Espínola C, Medina FJ (2009) Neuroprotective effect of carvedilol and melatonin on 3-nitropropionic acid-induced neurotoxicity in neuroblastoma. J Physiol Biochem 65:291-296
130. 2+ mediated permeability transition and beyond in rat brain astrocytes. J Pineal Res 48:20-38
131. Wang X, Sirianni A, Pei Z (2011) The melatonin MT1 receptor axis modulates mutant Huntingtin-mediated toxicity. J Neurosci 31:14496-14507
132. 10 and remacemide in transgenic mouse models of Huntington's disease. J Neurosci 22:1592-1599
133. 10 formulations in Huntington's disease mice. Biochim Biophys Acta 1762:616-626
134. Rice-Evans CA, Miller NJ, Paganga G (1996) Structure-antioxidant activity relationships of flavonoids and phenolic acids. Free Radic Biol Med 20:933-956 (Pubitemid 26157509)
135. Karuppagounder SS, Madathil SK, Pandey M, Haobam R, Rajamma U, Mohanakumar KP (2013) Quercetin up-regulates mitochondrial complex-I activity to protect against programmed cell death in rotenone model of Parkinson's disease in rats. Neuroscience 236:136-148
136. Boer VC, Dihal AA, van der Woude H (2005) Tissue distribution of quercetin in rats and pigs. J Nutr 135:1718-1725 (Pubitemid 40980724)
137. Sandhir R, Mehrotra A (2013) Quercetin supplementation is effective in improving mitochondrial dysfunctions induced by 3-nitropropionic acid: implications in Huntington's disease. Biochim Biophys Acta 1832:421-430
138. Chakraborty J, Singh R, Dutta D, Naskar A, Usha R, Mohanakumar KP (2013) Quercetin improves behavioral deficiencies, restores astrocytes and microglia, and reduces serotonin metabolism in 3-nitropropionic acid-induced rat model of Huntington's disease. CNS Neurosci Ther 20:10-9. doi:10.1111/cns.12189
139. Sandhir R, Sood A, Mehrotra A, Kamboj SS (2012) N-Acetylcysteine reverses mitochondrial dysfunctions and behavioral abnormalities in 3-nitropropionic acid-induced Huntington's disease. Neurodegener Dis 9:145-157
140. Banaclocha M, Martínez N (1999) N-acetylcysteine elicited increase in cytochrome c oxidase activity in mice synaptic mitochondria. Brain Res 842:249-251 (Pubitemid 29447877)
141. Banaclocha M (2000) N-acetylcysteine elicited increase in complex I activity in synaptic mitochondria from aged mice: implications for treatment of Parkinson's disease. Brain Res 859:173-175
142. Keeney PM, Quigley CK, Dunham LD (2009) Mitochondrial gene therapy augments mitochondrial physiology in a Parkinson's disease cell model. Hum Gene Ther 20:897-907
143. Andreassen OA, Ferrante RJ, Dedeoglu A, Beal MF (2001) Lipoic acid improves survival in transgenic mouse models of Huntington's disease. Neuroreport 12:3371-3373 (Pubitemid 33010674)
144. Gil JM, Leist M, Popovic N, Brundin P, Petersén A (2004) Asialoerythropoietin is not effective in the R6/2 line of Huntington's disease mice. BMC Neurosci 5:17
145. Nguyen T, Hamby A, Massa SM (2005) Clioquinol down-regulates mutant Huntingtin expression in vitro and mitigates pathology in a Huntington's disease mouse model. Proc Natl Acad Sci USA 102:11840-11845 (Pubitemid 41170812)
146. Duan W, Guo Z, Jiang H, Ladenheim B, Xu X, Cadet JL, Mattson MP (2004) Paroxetine retards disease onset and progression in Huntingtin mutant mice. Ann Neurol 55:590-594 (Pubitemid 38391979)
147. Gardian G, Browne SE, Choi DK (2005) Neuroprotective effects of phenylbutyrate in the N171-82Q transgenic mouse model of Huntington's disease. J Biol Chem 280:556-563 (Pubitemid 40165021)
148. Kieburtz K, Feigin A, McDermott M (1996) A controlled trial of remacemide hydrochloride in Huntington's disease. Mov Disord 11:273-277 (Pubitemid 26138825)
149. Huntington Study Group (2001) A randomized, placebo-controlled trial of coenzyme Q10 and remacemide in Huntington's disease. Neurology 57:397-404
150. Kalonia H, Kumar P, Kumar A, Nehru B (2009) Effects of caffeic acid, rofecoxib, and their combination against quinolinic acid-induced behavioral alterations and disruption in glutathione redox status. Neurosci Bull 25:343-352
151. Norflus F, Nanje A, Gutekunst CA (2004) Anti-inflammatory treatment with acetylsalicylate or rofecoxib is not neuroprotective in Huntington's disease transgenic mice. Neurobiol Dis 17:319-325 (Pubitemid 39345787)
152. Lee ST, Chu K, Park JE, Kang L, Ko SY, Jung KH, Kim M (2006) Memantine reduces striatal cell death with decreasing calpain level in 3-nitropropionic model of Huntington's disease. Brain Res 1118:199-207 (Pubitemid 44633871)
153. Verhagen Metman L, Morris MJ, Farmer C, Gillespie M, Mosby K, Wuu J, Chase TN (2002) Huntington's disease: a randomized, controlled trial using the NMDA-antagonist amantadine. Neurology 59:694-699
154. Lucetti C, Gambaccini G, Bernardini S, Dell'Agnello G, Petrozzi L, Rossi G, Bonuccelli U (2002) Amantadine in Huntington's disease: open-label video-blinded study. Neurol Sci 2:S83-S84 (Pubitemid 35355788)
155. Lucetti C, Del Dotto P, Gambaccini G (2003) IV amantadine improves chorea in Huntington's disease: an acute randomized, controlled study. Neurology 60:1995-1997 (Pubitemid 36736023)
156. O'Suilleabhain P, Dewey RB Jr (2003) A randomized trial of amantadine in Huntington disease. Arch Neurol 60:996-998 (Pubitemid 36858360)
157. Beister A, Kraus P, Kuhn W, Dose M, Weindl A, Gerlach M (2004) The N-methyl-D-aspartate antagonist memantine retards progression of Huntington's disease. J Neural Transm Suppl 68:117-122 (Pubitemid 39215445)
158. McAllister J, Ghosh S, Berry D, Park M, Sadeghi S, Wang KX, Parker WD, Swerdlow RH (2008) Effects of memantine on mitochondrial function. Biochem Pharmacol 75:956-964 (Pubitemid 351174116)
159. Ju WK, Kim KY, Angert M, Duong-Polk KX, Lindsey JD, Ellisman MH, Weinreb RN (2009) Memantine blocks mitochondrial OPA1 and cytochrome c release and subsequent apoptotic cell death in glaucomatous retina. Invest Ophthalmol Vis Sci 50:707-716
160. Dikshit P, Chatterjee M, Goswami A, Mishra A, Jana NR (2006) Aspirin induces apoptosis through the inhibition of proteasome function. J Biol Chem 281:29228-29235 (Pubitemid 44507066)
161. Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ (2003) Creatine therapy provides neuroprotection after onset of clinical symptoms in Huntington's disease transgenic mice. J Neurochem 85:1359-1367 (Pubitemid 36702548)
162. Shear DA, Haik KL, Dunbar GL (2000) Creatine reduces 3-nitropropionic- acid-induced cognitive and motor abnormalities in rats. Neuroreport 11:1833-1837 (Pubitemid 30429120)
163. Verbessem P, Lemiere J, Eijnde BO et al (2003) Creatine supplementation in Huntington's disease: a placebo-controlled pilot trial. Neurology 61:925-930 (Pubitemid 37248646)
164. Hersch SM, Gevorkian S, Marder K et al (2006) Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2′dG. Neurology 66:250-252 (Pubitemid 43970166)
165. Branovets J, Sepp M, Kotlyarova S et al (2013) Unchanged mitochondrial organization and compartmentation of high-energy phosphates in creatine-deficient GAMT- /- mouse hearts. Am J Physiol Heart Circ Physiol 305:H506-H520
166. Ribeiro M, Silva AC, Rodrigues J, Naia L, Rego AC (2013) Oxidizing effects of exogenous stressors in Huntington's disease knock-in striatal cells: protective effect of cystamine and creatine. Toxicol Sci 136:487-499
167. Andreassen OA, Ferrante RJ, Huang HM et al (2001) Dichloroacetate exerts therapeutic effects in transgenic mouse models of Huntington's disease. Ann Neurol 50:112-117
168. Miquel E, Cassina A, Martínez-Palma L et al (2013) Modulation of astrocytic mitochondrial function by dichloroacetate improves survival and motor performance in inherited amyotrophic lateral sclerosis. PLoS One 7:e34776
169. Zucker B, Ludin DE, Gerds TA, Lücking CH, Landwehrmeyer GB, Feuerstein TJ (2004) Gabapentin-lactam, but not gabapentin, reduces protein aggregates and improves motor performance in a transgenic mouse model of Huntington's disease. Naunyn Schmiedebergs Arch Pharmacol 370:131-139 (Pubitemid 39222865)
170. Pielen A, Kirsch M, Hofmann HD, Feuerstein TJ, Lagrèze WA (2004) Retinal ganglion cell survival is enhanced by gabapentinlactam in vitro: evidence for involvement of mitochondrial KATP channels. Graefes Arch Clin Exp Ophthalmol 242:240-244 (Pubitemid 38477210)
171. Wu J, Tang T, Bezprozvanny I (2006) Evaluation of clinically relevant glutamate pathway inhibitors in in vitro model of Huntington's disease. Neurosci Lett 407:219-223 (Pubitemid 44402868)
172. Kumar P, Kalonia H, Kumar A (2012) Possible GABAergic mechanism in the neuroprotective effect of gabapentin and lamotrigine against 3-nitropropionic acid induced neurotoxicity. Eur J Pharmacol 674:265-274
173. Mary V, Wahl F, Stutzmann JM (1995) Effect of riluzole on quinolinate-induced neuronal damage in rats: comparison with blockers of glutamatergic neurotransmission. Neurosci Lett 201:92-96
174. Kremer B, Clark CM, Almqvist EW et al (1999) Influence of lamotrigine on progression of early Huntington disease: a randomized clinical trial. Neurology 53:1000-1011 (Pubitemid 29442116)
175. Kim YJ, Ko HH, Han ES, Lee CS (2007) Lamotrigine inhibition of rotenone- or 1-methyl-4-phenylpyridinium-induced mitochondrial damage and cell death. Brain Res Bull 71:633-640 (Pubitemid 46209530)
176. de Tommaso M, Di Fruscolo O, Sciruicchio V et al (2005) Efficacy of levetiracetam in Huntington disease. Clin Neuropharmacol 28:280-284 (Pubitemid 44378619)
177. Gibbs JE, Walker MC, Cock HR (2006) Levetiracetam: antiepileptic properties and protective effects on mitochondrial dysfunction in experimental status epilepticus. Epilepsia 47:469-478 (Pubitemid 43351547)
178. Wood NI, Morton AJ (2003) Chronic lithium chloride treatment has variable effects on motor behaviour and survival of mice transgenic for the Huntington's disease mutation. Brain Res Bull 61:375-383 (Pubitemid 36945468)
179. Crespo-Biel N, Camins A, Pallàs M, Canudas AM (2009) Evidence of calpain/cdk5 pathway inhibition by lithium in 3-nitropropionic acid toxicity in vivo and in vitro. Neuropharmacology 56:422-428
180. Vestergaard P, Baastrup PC, Petersson H (1977) Lithium treatment of Huntington's chorea. A placebo-controlled clinical trial. Acta Psychiatr Scand 56:183-188 (Pubitemid 8171880)
181. Danivas V, Moily NS, Thimmaiah R, Muralidharan K, Purushotham M, Muthane U, Jain S (2013) Off label use of lithium in the treatment of Huntington's disease: a case series. Indian J Psychiatry 55:81-83
182. Repetto G, del Peso A, Sanz P, Repetto M (2001) In vitro effects of lithium and nickel at different levels on Neuro-2a mouse neuroblastoma cells. Toxicol In Vitro 15:363-368 (Pubitemid 32889659)
183. Chen M, Ona VO, Li M et al (2000) Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease. Nat Med 6:797-801 (Pubitemid 30469429)
184. Diguet E, Fernagut PO, Wei X, Du Y, Rouland R, Gross C, Bezard E, Tison F (2004) Deleterious effects of minocycline in animal models of Parkinson's disease and Huntington's disease. Eur J Neurosci 19:3266-3276 (Pubitemid 38859544)
185. Bantubungi K, Jacquard C, Greco A et al (2005) Minocycline in phenotypic models of Huntington's disease. Neurobiol Dis 18:206-217 (Pubitemid 40092910)
186. Bonelli RM, Hödl AK, Hofmann P, Kapfhammer HP (2004) Neuroprotection in Huntington's disease: a 2-year study on minocycline. Int Clin Psychopharmacol 19:337-342 (Pubitemid 39506988)
187. Gieseler A, Schultze AT, Kupsch K, Haroon MF, Wolf G, Siemen D, Kreutzmann P (2009) Inhibitory modulation of the mitochondrial permeability transition by minocycline. Biochem Pharmacol 77:888-896
188. Kupsch K, Hertel S, Kreutzmann P, Wolf G, Wallesch CW, Siemen D, Schönfeld P (2009) Impairment of mitochondrial function by minocycline. FEBS J 276:1729-1738
189. Ravikumar B, Vacher C, Berger Z (2004) Inhibition of mTOR induces autophagy and reduces toxicity of polyglutamine expansions in fly and mouse models of Huntington disease. Nat Genet 36:585-595 (Pubitemid 38715985)
190. Deepa SS, Walsh ME, Hamilton RT (2013) Rapamycin modulates markers of mitochondrial biogenesis and fatty acid oxidation in the adipose tissue of db/db mice. J Biochem Pharmacol Res 1:114-123
191. Liu J, Killilea DW, Ames BN (2002) Age-associated mitochondrial oxidative decay: improvement of carnitine acetyltransferase substrate-binding affinity and activity in brain by feeding old rats acetyl-L-carnitine and/or R-alpha-lipoic acid. Proc Natl Acad Sci USA 99:1876-1881 (Pubitemid 34168982)
192. Tanaka M, Machida Y, Niu S, Ikeda T, Jana NR, Doi H, Kurosawa M, Nekooki M, Nukina N (2004) Trehalose alleviates polyglutamine-mediated pathology in a mouse model of Huntington disease. Nat Med 10:148-154 (Pubitemid 38524884)
193. Yamaguchi R, Andreyev A, Murphy AN, Perkins GA, Ellisman MH, Newmeyer DD (2007) Mitochondria frozen with trehalose retain a number of biological functions and preserve outer membrane integrity. Cell Death Differ 14:616-624